A gene therapy targeting PCSK9 demonstrates sustained LDL reduction and early regression of atherosclerotic plaques in trial participants. This approach addresses a primary driver of cardiovascular disease progression, potentially shifting treatment from symptom management to causative intervention.
Key Points
- Gene therapy targeting PCSK9 achieves sustained LDL cholesterol reduction
- Early evidence shows regression of existing atherosclerotic plaques
- One-time intervention may replace chronic medication protocols
Longevity Analysis
Cardiovascular disease remains a leading cause of mortality; most interventions manage risk factors without addressing underlying plaque burden. A single genetic intervention that produces durable lipid lowering and plaque regression represents a fundamental shift in approach — from managing a chronic condition to potentially arresting or reversing its progression. The durability of the effect matters as much as the magnitude; if sustained without repeated dosing, this changes the calculus of treatment burden and compliance across decades of lifespan.
Original published by Peter Attia MD, by Peter Attia.